SEC 13F Intelligence

Bml Capital Management, LLC / ACRS

Bml Capital Management, LLC’s Aclaris Therapeutics Inc Position

Does Bml Capital Management, LLC own Aclaris Therapeutics Inc (ACRS)? Yes — 14.25M shares worth $53M (+34.31% of its 13F portfolio) as of Q1 2026.

Position Value
$53M
Q1 2026
Shares
14.25M
% of Portfolio
+34.31%
Quarters Held
10
currently held

Position History ACRS

Reported value by quarter
Q4 ’23: $685,762Q4 ’23Q1 ’24: $12MQ2 ’24: $14MQ2 ’24Q3 ’24: $16MQ4 ’24: $35MQ4 ’24Q1 ’25: $22MQ2 ’25: $20MQ2 ’25Q3 ’25: $27MQ4 ’25: $43MQ4 ’25Q1 ’26: $53Mfilingsflow.com
QuarterSharesValue% of Portfolio
Q1 202614.25M$53M+34.31%
Q4 202514.25M$43M+37.08%
Q3 202514.25M$27M+24.79%
Q2 202514.25M$20M+15.31%
Q1 202514.25M$22M+17.65%
Q4 202414.25M$35M+21.95%
Q3 202414.25M$16M+9.64%
Q2 202412.99M$14M+10.20%
Q1 20249.40M$12M+7.68%
Q4 2023653.1K$685,762+0.52%

Common-stock position only; options are excluded. Quarters where the fund filed no 13F or reported no position are absent. See Bml Capital Management, LLC’s full portfolio or all institutional holders of ACRS.